Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2026 Nov 19;22(11):e1012373. doi: 10.1371/journal.pgen.1012373

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

Jingyi Ke 1,2,3,4,5,6, Zi Wang 1,2,3,4,5,6, Zhengyang Guo 1,2,3,4,5,6, Guangshuo Ou 1,2,3,4,5,6,*, Wei Li 1,7,*
Editor: Bruce E Clurman8
PMCID: PMC13784607  PMID: 43056352

Abstract

Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhibitors such as trametinib undermines clinical benefits, and the mechanisms sustaining MAPK activity under treatment remain unclear. We developed a lin-45(V627E) Caenorhabditis elegans model to mimic oncogenic BRAF signaling and found that these animals exhibited high-dose trametinib resistance, as assessed by brood size. Transcriptomic analysis revealed increased egl-30 expression in worms resistant to high-dose trametinib. Genetic and pharmacological analyses implicated EGL-30/Gαq-PLC-PKC signaling in this high-dose resistance phenotype. In trametinib-resistant A375 melanoma cells, F2RL1, which encodes the Gαq-coupled GPCR PAR2, was upregulated compared with parental cells. Functional inhibition of PAR2 or downstream Gαq signaling reduced ERK phosphorylation and impaired the viability of trametinib-resistant melanoma cells. Furthermore, combined inhibition of MEK and Gαq-PLC-PKC signaling synergistically suppresses tumor growth and restores trametinib sensitivity in xenograft models. These findings uncover Gαq-associated signaling as a conserved contributor to trametinib resistance and a potential therapeutic vulnerability in BRAF-mutant melanoma.

Author summary

Targeted therapies against the MAPK pathway have greatly improved outcomes for patients with BRAF-mutant melanoma. However, most tumors eventually become resistant, limiting the long-term effectiveness of these treatments. The mechanisms that allow cancer cells to survive despite MAPK inhibition remain incompletely understood. In this study, we developed a genetically tractable Caenorhabditis elegans model carrying an oncogenic BRAF-like mutation and found that these animals exhibited resistance to high-dose treatment with the MEK inhibitor trametinib, as assessed by brood size. Using this model, we identified an important role for Gαq-PLC–PKC signaling in this resistance phenotype. We further found increased F2RL1 expression in trametinib-resistant human melanoma cells and showed that Gαq signaling contributes to the maintenance of their resistance to trametinib. Blocking Gαq signaling reduced MAPK activity and, when combined with MEK inhibition, restored drug sensitivity and inhibited tumor growth. Our work highlights the power of C. elegans genetics to uncover conserved mechanisms of cancer drug resistance and identifies GPCR-Gαq signaling as a promising target for improving the durability of MAPK-targeted therapies.

Introduction

Melanoma is a highly aggressive cancer with an increasing global incidence, and remains a leading cause of skin cancer-related mortality [1,2]. A defining feature of melanoma is the constitutive activation of the MAPK pathway, most commonly driven by BRAFV600 mutations [3]. Oncogenic BRAF triggers the RAF-MEK-ERK signaling cascade, promoting tumor growth and survival, providing a mechanistic basis for targeted therapies [4–7]. As a result, BRAF and MEK inhibitors (BRAFi/MEKi) have significantly improved clinical outcomes, and combination BRAFi/MEKi therapy is now the standard of care for patients with BRAF-mutant melanoma [8–10]. However, intrinsic and acquired resistance to these MAPK inhibitors remains a major challenge, limiting long-lasting therapeutic responses [11,12]. While genomic analyses of resistant tumors have identified diverse mechanisms of MAPK reactivation [13], the complexity and heterogeneity of these resistance pathways are not fully understood, in part due to the lack of genetically tractable models that can accurately replicate acquired BRAFV600E resistance.

Evolutionarily conserved model systems, such as Caenorhabditis elegans, provide powerful platforms to uncover the fundamental mechanisms of therapy resistance. C. elegans has proven to be a robust model for studying Ras-MAPK signaling [14], with highly conserved components including Ras/LET-60, RAF/LIN-45, MEK-2, and ERK/MPK-1 [15–18]. MAPK signaling in worms regulates key developmental processes [19–21]. Hyperactivation or inhibition of MAPK signaling produces quantifiable phenotypes, such as multivulva and vulvaless patterns, which can be used to evaluate drug responses [22–25]. Complete loss of MAPK pathway activity results in sterility, highlighting its essential biological role [26,27]. These features make C. elegans an ideal model for dissecting MAPK regulation and drug resistance.

Resistance to MAPK inhibitors in melanoma frequently arises through complex non-genetic mechanisms that restore MAPK pathway activity under therapeutic pressure [28]. MAPK reactivation can be driven by compensatory signaling circuits, including ABL1/2-mediated MEK/ERK/MYC reactivation, PI3K-AKT-mTOR activation, and SRC family kinase signaling [29–31]. Notably, translational control mediated by the eIF4F complex acts as a central node sustaining oncogenic and survival programs under BRAF and MEK inhibition [32]. In addition, metabolic reprogramming and post-translational signaling plasticity further sustain tumor survival, while receptor tyrosine kinases such as PDGFRB and EGFR contribute to bypass signaling [33–36]. Bypass signaling, however, is not restricted to receptor tyrosine kinases. G protein-coupled receptors (GPCRs) have emerged as key regulators of oncogenic signaling and cancer progression [37–39]. Among them, the protease-activated receptor PAR2 (F2RL1) promotes tumorigenesis in multiple cancer types [40–42]. Gαq signaling also sustains MAPK activity in GNAQ/GNA11-mutant uveal melanoma [43–46] However, it remains unclear whether GPCR-Gαq signaling contributes to adaptive escape from MAPK inhibition in cutaneous BRAFV600E melanoma.

Here, we developed a lin-45(V627E) C. elegans model exhibiting high-dose trametinib resistance, as assessed by brood size, to investigate signaling pathways that contribute to drug resistance. Using this system, we identified EGL-30/Gαq- PLC-PKC signaling as contributors to this resistance phenotype. This mechanism is conserved in human BRAFV600E melanoma, suggesting a potential strategy for overcoming resistance to MEK inhibitors.

Results

A lin-45(V627E) C. elegans model exhibits high-dose trametinib resistance

To investigate mechanisms of resistance to MEK inhibition in a genetically tractable in vivo system, we developed a Caenorhabditis elegans model harboring the lin-45(syb4962) allele, which encodes the oncogenic LIN-45(V627E) substitution corresponding to human BRAFV600E (S1A Fig). Remarkably, lin-45(V627E) animals continued to produce progeny at 100 μM trametinib, a concentration that completely abolished fertility in wild-type worms, revealing an unanticipated and robust resistance phenotype (Fig 1A and B). To assess the resistance profile, we exposed both wild-type and lin-45(V627E) animals to increasing concentrations of trametinib (1–100 μM) and measured fertility in the F1 generation (Fig 1A). In wild-type animals, trametinib caused a dose-dependent loss of fertility, with complete sterility and an absence of recognizable oocytes observed at 10 μM and 100 μM (Fig 1B and S1B-S1C Fig). In contrast, lin-45(V627E) mutants exhibited a nonlinear dose response: while 10 μM trametinib nearly abolished fertility, increasing the dose to 100 μM restored brood size to approximately 63% of the DMSO control levels (Fig 1B and S2C Fig), indicating a capacity for resistance. Consistent with the brood size phenotype, most lin-45(V627E) mutants lacked recognizable oocytes at 10 μM trametinib, whereas enlarged oocyte-like compartments were observed in a subset of animals at 100 μM trametinib (S1B and S1C Fig).

Fig 1. A lin-45(V627E) C. elegans model exhibits high-dose trametinib resistance.

Fig 1

(A) Experimental workflow for brood size quantification in wild-type (WT) and lin-45(V627E) animals. P0 animals were cultured on NGM agar plates containing DMSO vehicle or trametinib (Tram; 1, 10, or 100 μM). F1 progeny at the L4 stage were transferred individually to fresh plates under the same treatment conditions and their total brood sizes were determined. (B) Dose-dependent effects of trametinib (Tram) on brood size of WT and lin-45(V627E) F1 animals. Each point represents one animal, and bars show the mean ± SD. Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. n > 30. ***P < 0.001, ****P < 0.0001; ns, not significant. (C) Representative bright-field images of vulva from WT and lin-45(V627E) animals treated with DMSO or 10 μM trametinib (Tram). Dashed boxes indicate the vulval region. Additional representative images are shown in S1D Fig. Scale bar, 10 μm. (D) Quantification of vulval phenotypes in WT and lin-45(V627E) animals treated with DMSO or different concentrations of trametinib (Tram). The exact numbers of animals examined are shown in parentheses. Within each genotype, phenotype distributions at each trametinib concentration were compared with the corresponding DMSO control using two-sided Fisher’s exact tests. P values were adjusted using the Holm method. (E) Representative bright-field images of vulval morphology in day 1 adult WT and lin-45(V627E) animals fed bacteria carrying either the empty control vector or a lin-45 RNAi construct. Percentages indicate the proportion of animals displaying the indicated vulval phenotype. The exact numbers of animals examined are shown in (F). Scale bar, 25 μm. (F) Quantification of vulval phenotypes in WT and lin-45(V627E) animals fed control or lin-45 RNAi bacteria. The exact numbers of animals examined are shown in parentheses. Phenotype distributions were compared between RNAi treatments within each genotype using two-sided Fisher’s exact tests. P values were adjusted using the Holm method. ****P < 0.0001; ns, not significant.

Vulval phenotypes were tracked alongside fertility outcomes as secondary phenotypic readouts. Under DMSO treatment, lin-45(V627E) mutants displayed a fully penetrant protruding vulva (Pvl) phenotype (Fig 1C and D). Feeding RNAi targeting lin-45 partially suppressed this phenotype (Fig 1E and F), supporting a contribution of LIN-45 activity to the Pvl phenotype. Low and intermediate doses of trametinib suppressed the Pvl phenotype, whereas high-dose treatment (100 μM) partially restored this phenotype in lin-45(V627E) mutants (Fig 1C and 1D and S1D Fig). These findings establish lin-45(V627E) worms as a genetically tractable in vivo model for investigating high-dose trametinib resistance.

Transcriptomic and genetic analyses implicate EGL-30/Gαq in the resistant state

To identify pathways associated with high-dose trametinib resistance, we performed RNA sequencing on trametinib-sensitive (10 μM) and trametinib-resistant (100 μM) lin-45(V627E) F1 animals. Principal component analysis revealed clear segregation between the two conditions, indicating a distinct transcriptional program associated with resistance (S2A Fig). Differential expression analysis identified 443 genes significantly upregulated in resistant animals (fold change > 2, Padj < 0.05; Fig 2A).

Fig 2. Reduced EGL-30/Gαq activity or PLC–PKC inhibition compromises high-dose trametinib resistance in lin-45(V627E) mutants.

Fig 2

(A) Volcano plot of differentially expressed genes in lin-45(V627E) F1 animals treated with 100 μM trametinib relative to 10 μM trametinib. Upregulated genes are shown in red and downregulated genes in blue. Cutoffs: fold change > 2 and adjusted P value (Padj) < 0.05. n = 3 independent biological replicates per condition. (B) Gene Ontology (GO) enrichment analysis of upregulated genes in lin-45(V627E) F1 animals treated with 100 μM trametinib relative to 10 μM trametinib. Dot size represents gene counts, and color indicates enrichment significance. (C) Schematic overview of the EMS-based genetic suppressor screen in lin-45(V627E) animals to identify mutations that suppress the protruding-vulva phenotype. (D) Representative images of vulval phenotypes of lin-45(V627E), lin-45(V627E); egl-30(R25C), lin-45(V627E); egl-30(S6F), and lin-45(V627E); egl-30(c.594-1G > A) mutants. Scale bar, 10 μm. (E) Quantification of vulval phenotypes shown in (D). n > 50 animals per genotype. (F) Dose-dependent effects of trametinib (Tram) on brood size in lin-45(V627E); egl-30(R25C) F1 animals. Statistical analysis was performed using Kruskal-Wallis test followed by Dunn’s multiple comparisons test. n > 30 animals per condition. ****P < 0.0001; ns, not significant. (G) Brood size of WT, lin-45(V627E) and lin-45(V627E); egl-30(R25C) F1 animals treated with 100 μM trametinib (Tram). Statistical analysis was performed using Kruskal-Wallis test followed by Dunn’s multiple comparisons test. n > 35 animals per genotype. ****P < 0.0001. (H) Brood sizes of lin-45(V627E) F1 animals treated with DMSO, 100 μM trametinib (Tram), 50 μM U73122, 50 μM sotrastaurin (Sotra), or indicated drug combinations. Statistical analysis was performed using the Kruskal-Wallis test followed by Dunn’s multiple comparisons test. n > 35 animals per condition. ****P < 0.0001.

Gene ontology analysis revealed strong enrichment for G-protein-coupled signaling, with egl-30, encoding the sole C. elegans Gαq ortholog, among the most significantly upregulated components (fold change = 3.02, adjusted P-value (Padj) < 0.001; Fig 2A and B, S2B Fig and S1 Table). This transcriptional signature suggested that enhanced Gαq signaling correlates with the resistant state.

Independently, an unbiased forward genetic suppressor screen identified egl-30(cas30009), a recessive allele encoding the R25C substitution, as a suppressor of the Pvl phenotype of lin-45(V627E) mutants (Fig 2C). Introduction of two additional egl-30 loss-of-function alleles, egl-30(ad806) encoding EGL-30(S6F) and egl-30(n686) carrying the c.594 − 1G > A splice-acceptor-site variant, into the lin-45(V627E) background similarly suppressed the Pvl phenotype (Fig 2D and E), reinforcing a correlative link between reduced Gαq activity and attenuation of lin-45(V627E)-driven phenotypes. Together, the transcriptomic and genetic data converge on EGL-30/Gαq as a key determinant of the trametinib-resistant state.

Reduced EGL-30/Gαq activity compromises high-dose trametinib resistance

To directly assess the role of EGL-30/Gαq in resistance, we examined fertility in lin-45(V627E); egl-30(R25C) double mutants. Under DMSO treatment, these animals already exhibited impaired reproduction, producing 13 ± 7 progeny per animal (mean ± SD; Fig 2F). The double mutants continued to produce progeny at 1 μM trametinib but produced no progeny at 10 μM (Fig 2F). Under 100 μM trametinib treatment, lin-45(V627E) single mutants retained approximately 63% of their DMSO brood production (153 ± 61 versus 241 ± 59 progeny), whereas lin-45(V627E); egl-30(R25C) double mutants retained only approximately 15% of their DMSO brood production (2 ± 2 versus 13 ± 7 progeny) (Figs 1B and 2F-G). Thus, the recovery of brood production at 100 μM trametinib observed in lin-45(V627E) animals was markedly attenuated by egl-30(R25C), supporting a contribution of EGL-30/Gαq to high-dose trametinib resistance. However, because the baseline brood size of lin-45(V627E); egl-30(R25C) double mutants was already substantially reduced under DMSO, these data do not fully exclude an interaction between trametinib treatment and pre-existing reproductive impairment.

EGL-30/Gαq-associated PLC-PKC signaling contributes to high-dose trametinib resistance

Gαq classically activates phospholipase Cβ (PLCβ), generating diacylglycerol and activating protein kinase C (PKC), which can promote MAPK signaling [47]. We therefore examined whether PLC-PKC signaling contributes to high-dose trametinib resistance (S2D Fig). lin-45(V627E) animals were treated with U73122, which is widely used as a PLC inhibitor, or with the PKC inhibitor sotrastaurin, alone or in combination with trametinib. Neither inhibitor alone substantially reduced brood production (Fig 2H, S2E Fig). In contrast, co-treatment with 100 μM trametinib and either inhibitor resulted in near-complete loss of brood production, phenocopying genetic suppression of egl-30 (Fig 2H, S2E Fig). These pharmacological findings support a contribution of PLC-PKC signaling to high-dose trametinib resistance. However, they neither identify the specific PLC isoform involved nor establish whether PLC-PKC signaling acts through crosstalk with the RAF–MEK–ERK pathway or influences reproductive output through a parallel mechanism.

Gαq-PLC-PKC inhibition synergizes with MEK blockade in BRAFV600E melanoma cells and xenografts

To determine whether this resistance mechanism is conserved in human cancer, we examined BRAFV600E A375 melanoma cells. shRNA-mediated knockdown of GNAQ and GNA11 (Fig 3A) significantly lowered the IC50 of trametinib in cell viability assays (Fig 3B and C). ERK phosphorylation was also lower in Gαq/11-depleted cells under DMSO and 0.1 nM trametinib treatment conditions (Fig 3D), supporting a contribution of Gαq/11 to MAPK signaling. Pharmacological inhibition of PLC or PKC in combination with trametinib also produced robust synergistic suppression of cell proliferation, with combination index values <0.3 across most dose combinations (Fig 3E-F). Correspondingly, ERK phosphorylation was more effectively suppressed by combination therapy than by either agent alone (Fig 3G). In parallel, both genetic knockdown and pharmacological inhibition of Gαq signaling markedly impaired clonogenic growth in A375 cells (S3A-S3C Fig), reinforcing the contribution of Gαq to proliferative capacity under targeted therapy pressure. These findings recapitulate the genetic interactions observed in C. elegans, supporting a role for Gαq-associated signaling in trametinib resistance across the models examined.

Fig 3. Synergistic suppression of A375 cell proliferation by combined Gαq/11-PLC-PKC blockade and MEK inhibition.

Fig 3

(A) Knockdown efficiency of GNAQ and GNA11 in A375 cells transduced with shRNA targeting both genes (shGαq/11), assessed by immunoblotting. (B) A375 cells transduced with control vector (Ctrl) or shGαq/11 were treated with vehicle or trametinib for 72 h. Cell viability was measured using the Cell-ATP viability detection Kit, and dose-response curves are shown (mean ± SD, n = 3 independent experiments). (C) IC50 values of trametinib in Ctrl- and shGαq/11-transduced A375 cells. n = 3–5 independent experiments. **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons test. (D) Western blot analysis of indicated proteins in Ctrl- or shGαq/11-transduced A375 cells treated with DMSO or trametinib at the indicated concentrations for 24 h. Representative blots (left; n = 3 independent experiments) and quantification of p-ERK/ERK ratios (right) are shown. **P < 0.01, ****P < 0.0001; ns, not significant; two-way ANOVA with Tukey’s multiple comparisons test. (E) Dose-response curves of cell viability (left) and Chou-Talalay combination index (CI) plots (right) for A375 cells treated with U73122 in combination with trametinib at the indicated concentrations for 72 h (mean ± SD, n = 3). CI < 0.3 indicates strong synergy (red), 0.3-0.9 synergy, 0.9-1.1 additive effects, and ≥ 1.1 antagonism (blue). (F) Dose-response curves of cell viability (left) and CI plots (right) for A375 cells treated with sotrastaurin in combination with trametinib at the indicated concentrations for 72 h (mean ± SD, n = 3). (G) Western blot analysis of indicated proteins in A375 cells treated with DMSO, 10 μM sotrastaurin, or 5 μM U73122, alone or in combination with trametinib at the indicated concentrations for 24 h. Representative blots (left; n = 3 independent experiments) and quantification of p-ERK levels (right) are shown. *P < 0.05, **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons test.

We next evaluated the therapeutic relevance in vivo using A375 xenografts in the mouse model. While trametinib, U73122, or sotrastaurin monotherapy delayed tumor growth, combination treatments produced substantially enhanced tumor suppression (Fig 4A-F). Trametinib-sotrastaurin regimens caused no overt toxicity, while U73122-containing combinations induced modest weight loss without additional adverse effects (S4A-S4B Fig). The animals remained otherwise healthy, indicating dose-dependent systemic effects. These data establish that pharmacological disruption of Gαq-PLC-PKC signaling enhances MEK inhibitor efficacy in vivo.

Fig 4. PLC-PKC blockade enhances MEK inhibitor efficacy in A375 xenograft models.

Fig 4

(A-C) Parental A375 xenografts were randomized into treatment groups and administered vehicle, trametinib (0.2 mg/kg), U73122 (50 mg/kg) or their combination when mean tumor volume reached ~250 mm3 (n = 17 per group). Tumor growth curves (A), endpoint tumor weights (B), and representative excised tumors (C) are shown. (D-F) Parental A375 xenografts treated with vehicle, trametinib (0.2 mg/kg), sotrastaurin (Sotra; 80 mg/kg), or their combination (n = 12 per group). Tumor growth curves (D), endpoint tumor weights (E), and representative excised tumors (F) are shown. Data represent mean ± SEM. Treatments were initiated when mean tumor volume reached ~250 mm3. Statistical significance was determined by two-way ANOVA for tumor growth and one-way ANOVA for tumor weight, followed by Tukey’s multiple comparisons test, except for the comparison in (E) between the two indicated time-matched groups, which was analyzed using an unpaired two-tailed t-test. **P < 0.01, ***P < 0.001, ****P < 0.0001.

Gαq-PLC-PKC signaling is required to maintain acquired trametinib resistance

We next investigated whether Gαq signaling is required for maintaining an established resistant state in cells that have already developed resistance to MEK inhibition. To address this, we generated trametinib-resistant A375 cells (A375-TR) using an established protocol of chronic drug exposure [48]. A375-TR cells exhibited a > 500-fold increase in trametinib IC50, sustained ERK activation, and enhanced clonogenic capacity under high-dose treatment (Figs 5A-5C, S5A). Genetic suppression of GNAQ and GNA11 markedly reduced ERK phosphorylation and restored trametinib sensitivity in A375-TR cells (Fig 5D-G). Likewise, pharmacological inhibition of PLC or PKC impaired viability of resistant cells and strongly synergized with trametinib (Fig 5H-J). Consistently, both genetic knockdown and pharmacological inhibition of Gαq signaling substantially suppressed clonogenic outgrowth of A375-TR cells, indicating loss of long-term proliferative capacity under targeted therapy pressure (S5B-S5D Fig). These data demonstrate that persistent Gαq-PLC-PKC signaling is essential to sustain MAPK activity and maintain the resistant state.

Fig 5. Synergistic suppression of trametinib-resistant A375 (A375-TR) cell proliferation by dual Gαq/11-PLC-PKC and MEK blockade.

Fig 5

(A) Parental A375 and trametinib-resistant A375 (A375-TR) cells were treated with vehicle or trametinib for 72 h. Cell viability was measured using the Cell-ATP viability detection kit, and dose-response curves are shown (mean ± SD, n = 3 independent experiments). (B) IC50 values of trametinib in A375 and A375-TR cells. n = 3, ***P < 0.001; unpaired two-tailed t-test. (C) Western blot analysis of the indicated proteins in A375 and A375-TR cells treated with DMSO or 10 nM trametinib for 24 h. Representative blots (left) and quantification of p-ERK/ERK levels (right) are shown (n = 3 independent experiments). For each cell line, p-ERK/ERK after 10 nM trametinib treatment was normalized to the corresponding p-ERK/ERK under DMSO treatment, which was set to 1. *** P < 0.001; unpaired two-tailed t-test. (D) Knockdown efficiency of GNAQ and GNA11 in A375-TR cells transduced with shGαq/11, assessed by immunoblotting. (E) Ctrl- and shGαq/11-transduced A375-TR cells were treated with vehicle or trametinib for 72 h. Cell viability was measured using the Cell-ATP viability detection kit, and dose-response curves are shown (mean ± SD, n = 3 independent experiments). (F) IC50 values of trametinib in Ctrl- and shGαq/11-transduced A375-TR cells. n = 3 independent experiments. **P < 0.01, ***P < 0.001; one-way ANOVA with Tukey’s multiple comparisons test. (G) Western blot analysis of indicated proteins in Ctrl- or shGαq/11-transduced A375-TR cells treated with DMSO or trametinib at the indicated concentrations for 24 h. Representative blots (left; n = 3 independent experiments) and quantification of p-ERK/ERK ratios (right) are shown. ns, not significant; **P < 0.01, ****P < 0.0001; two-way ANOVA with Tukey’s multiple comparisons test. (H) Dose-response curves of cell viability (left) and CI plots (right) for A375-TR cells treated with U73122 in combination with trametinib at the indicated concentrations for 72 h (mean ± SD, n = 3). (I) Dose-response curves of cell viability (left) and CI plots (right) for A375-TR cells treated with sotrastaurin in combination with trametinib at the indicated concentrations for 72 h (mean ± SD, n = 3). (J) Western blot analysis of indicated proteins in A375-TR cells treated with DMSO, 10 μM sotrastaurin, or 5 μM U73122, alone or in combination with trametinib at the indicated concentrations for 24 h. Representative blots (left; n = 3 independent experiments) and quantification of p-ERK/ERK ratios (right) are shown. **P < 0.01, ***P < 0.001; one-way ANOVA with Tukey’s multiple comparisons test.

We examined whether this dependency operates in vivo. Xenografts established from A375-TR cells were refractory to trametinib treatment, confirming their resistant state. In contrast, inhibition of PLC or PKC alone modestly suppressed tumor growth, while combination treatment with trametinib led to marked tumor regression (Fig 6A-F). As expected, trametinib-sotrastaurin treatment caused no detectable adverse effects. We reduced the dosing frequency of the PLC inhibitor U73122 from three to two administrations per week, preserving robust antitumor efficacy while significantly alleviating treatment-associated body weight loss, indicating an improved therapeutic window (S6A-S6B Fig).

Fig 6. PLC-PKC blockade enhances MEK inhibitor efficacy in A375-TR xenograft models.

Fig 6

(A-C) Trametinib-resistant A375-TR xenografts treated with vehicle, trametinib (0.2 mg/kg), U73122 (50 mg/kg), or their combination (n = 10 per group). Tumor growth curves (A), endpoint tumor weights (B), and representative excised tumors (C) are shown. (D-F) A375-TR xenografts treated with vehicle, trametinib (0.2 mg/kg), sotrastaurin (Sotra; 80 mg/kg), or their combination (n = 10 per group). Tumor growth curves (D), endpoint tumor weights (E), and representative excised tumors (F) are shown. (G-I) A375-TR xenografts transduced with control vector (Ctrl) or shGαq/11 #2 and treated with vehicle or trametinib (0.2 mg/kg) (n = 18 mice per group). Tumor growth curves (G), endpoint tumor weights (H), and representative excised tumors (I) are shown. Data represent mean ± SEM in (A, D, G) and mean ± SD in (B, E, H). Treatments were initiated when the mean tumor volume reached approximately 100–150 mm³ for the pharmacological experiments (A-F) and 150–250 mm³ for the shGαq/11#2 experiments (G-I). Statistical significance was determined by two-way ANOVA for tumor growth and one-way ANOVA for tumor weight, followed by Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.

To genetically validate the requirement for Gαq signaling in an established resistant state in vivo, we generated xenografts from GNAQ/11-depleted A375-TR cells. These tumors exhibited significantly impaired growth compared with empty vector controls. Notably, trametinib treatment effectively suppressed growth of GNAQ/11-depleted xenografts, demonstrating that genetic disruption of Gαq signaling restores MEK inhibitor sensitivity in resistant tumors (Fig 6G-I, S6C Fig). Collectively, Gαq-PLC-PKC signaling is functionally required to maintain acquired trametinib resistance in vivo, and disruption of this pathway restores therapeutic vulnerability to MEK blockade.

The PAR2-encoding Gene F2RL1 Is upregulated in trametinib-resistant A375 cells

To explore expression changes in Gαq-associated signaling genes in patients with MAPK inhibitor resistance, we analyzed RNA-seq and microarray datasets from melanoma patients before treatment and after acquisition of resistance to BRAFi and/or MEKi therapy [34,35,49–52]. We focused on the Gαq subunit genes GNAQ and GNA11, as well as F2RL1, which encodes the Gαq-coupled receptor PAR2. Across 39 matched pretreatment/post-treatment sample pairs, higher post-treatment expression was observed in a subset of cases for each gene: 18/39 for F2RL1, 21/39 for GNA11, and 20/39 for GNAQ (Fig 7A and S7A-S7C Fig). However, none of the distributions differed significantly from an equal proportion of higher and lower post-treatment expression (Fig 7A). Thus, the observed direction of expression change varied across cases and provided no evidence of a cohort-wide directional increase in any of these genes.

Fig 7. F2RL1 (PAR2) is upregulated and contributes to ERK phosphorylation and cell viability in A375-TR cells.

Fig 7

(A) Changes in F2RL1 (PAR2), GNAQ, and GNA11 mRNA expression across 39 matched pretreatment/post-treatment melanoma sample pairs from public RNA-seq (GSE50535 and GSE77940) and microarray (GSE50509 and GSE61992) datasets after BRAFi, MEKi, or BRAFi/MEKi treatment. Each pair was classified as having higher or lower post-treatment expression solely according to the direction of the paired change, with no fold-change or statistical-significance threshold. Numbers in the bars indicate sample-pair counts. None of the distributions differed significantly from an equal proportion of higher and lower expression (F2RL1, P = 0.75; GNAQ, P = 1.00; GNA11, P = 0.75; two-sided exact binomial tests). (B) Volcano plot of differentially expressed genes in trametinib-resistant A375 cells (A375-TR) treated with 10 nM trametinib relative to parental A375 cells treated under the same conditions. Upregulated genes are shown in red and downregulated genes in blue. Cutoffs: fold change > 2 and adjusted P value (Padj) < 0.05. n = 3 independent biological replicates per condition. (C) Knockdown efficiency of F2RL1 in A375-TR cells transduced with shRNA targeting F2RL1 (shF2RL1), assessed by immunoblotting. (D) Western blot analysis of indicated proteins in Ctrl- or shF2RL1-transduced A375-TR cells maintained in 10 nM trametinib. Representative blots (top; n = 3 independent experiments) and quantification of p-ERK/ERK ratios (bottom) are shown. **P < 0.01, ***P < 0.001; one-way ANOVA with Tukey’s multiple comparisons test. (E) Western blot analysis of indicated proteins in A375-TR cells treated with DMSO or AZ3451 at the indicated concentrations for 96 h. Representative blots (top; n = 3 independent experiments) and quantification of p-ERK/ERK ratios (bottom) are shown. **P < 0.01, ***P < 0.001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. (F) Cell viability of A375-TR cells treated with DMSO or the indicated concentrations of AZ3451 for 96 h, measured using the Cell-ATP viability detection kit. Cell viability is expressed as a percentage of the DMSO-treated control (n = 3 independent experiments). ****P < 0.0001; one-way ANOVA followed by Tukey’s multiple comparisons test.

We next examined F2RL1 expression in our experimental model. RNA-seq analysis showed that F2RL1 was significantly upregulated in A375-TR cells compared with parental A375 cells (Fig 7B), highlighting transcriptional upregulation of GPCR-Gαq signaling components as a recurrent feature of trametinib resistance across our worm and melanoma models.

The GPCR PAR2 contributes to ERK phosphorylation and cell viability in trametinib-resistant melanoma cells

Given the upregulation of F2RL1 in A375-TR cells, we next tested whether PAR2 contributes to ERK signaling in resistant melanoma cells. To this end, we generated three independent shRNA constructs targeting PAR2 (F2RL1), all of which effectively reduced PAR2 level (Fig 7C). PAR2 depletion markedly diminished ERK phosphorylation in A375-TR cells (Fig 7D), supporting a contribution of PAR2 to ERK signaling in the resistant cells.

We next evaluated the effect of pharmacologically inhibiting PAR2 with the PAR2 antagonist AZ3451. AZ3451 reduced p-ERK/ERK levels in A375-TR cells in a concentration-dependent manner, with significant effects observed at the higher concentrations tested (Fig 7E). AZ3451 also produced a concentration-dependent reduction in A375-TR cell viability (Fig 7F). Together, these genetic and pharmacological findings indicate that PAR2 contributes to the maintenance of ERK phosphorylation and cell viability in A375-TR cells, consistent with its proposed role upstream of Gαq-associated MAPK signaling.

Discussion

This study uncovers a pivotal role for GPCR-Gαq-PLC-PKC signaling in mediating adaptive resistance to trametinib in BRAFV600E melanoma, offering insights into how MAPK pathway output is sustained despite MEK inhibition. The ability of lin-45(V627E) worms to remain fertile under MEK inhibition—a condition that would otherwise induce sterility in wild-type worms—enabled the identification of signaling components contributing to the high-dose resistance phenotype (Fig 1A-B). Importantly, this finding was validated in human melanoma cell lines (Figs 3 and 5) and xenografts (Fig 4A-F), demonstrating that the cross-species approach used here—starting with mechanistic discovery in worms followed by translational validation in mammalian systems—can effectively uncover conserved resistance pathways that might be obscured in more complex tumor systems.

The therapeutic relevance of these findings is further supported by our in vivo data. Trametinib-resistant xenografts were resensitized to therapy when Gαq-PLC-PKC signaling was inhibited (Fig 6A-F). Combined MEK and PKC inhibition induced marked tumor suppression with limited systemic toxicity, indicating a favorable therapeutic window (S6B Fig). This underscores the potential of co-targeting MEK and Gαq-PKC signaling as an effective strategy to overcome acquired resistance in MAPK-driven cancers. However, because trametinib, sotrastaurin, and U73122 were administered systemically, our pharmacological xenograft experiments cannot distinguish their direct effects on melanoma cells from effects mediated through host tissues. The GNAQ/GNA11-depleted A375-TR xenografts (Fig 6G-I) provide additional support for a tumor-cell contribution of Gαq/11 because the genetic perturbation was introduced into the implanted melanoma cells, but do not exclude host-mediated contributions to the in vivo pharmacological response. Our findings also implicate PAR2, a Gαq-coupled GPCR [53], as a potential therapeutic target in A375-TR cells. F2RL1 expression was increased in A375-TR cells compared with parental A375 cells (Fig 7B), and its inhibition—either genetically or pharmacologically—resulted in significant suppression of ERK phosphorylation and cell viability (Fig 7D-F). These findings position PAR2 as a potential upstream regulator of Gαq-dependent MAPK signaling and a candidate therapeutic target in trametinib-resistant BRAF(V600E) melanoma cells.

Importantly, this study highlights the power of model organisms—particularly C. elegans—as genetically tractable platforms for uncovering conserved mechanisms of therapeutic resistance. The capacity to perform unbiased, large-scale genetic and pharmacological screens in C. elegans enables rapid identification of resistance pathways and druggable vulnerabilities that may remain obscured in mammalian systems. Moreover, the ease of generating resistant mutants and mapping genetic interactions allows systematic dissection of complex adaptive signaling networks. Together, these features position C. elegans as a powerful discovery engine for revealing evolutionarily conserved resistance mechanisms and informing therapeutic strategies in human cancer.

Notably, analysis of the GSE245262 dataset, which profiles NRASQ61L melanoma cells rendered resistant to combined BRAF and MEK inhibition, revealed a striking upregulation of the F2RL1 (PAR2) upon acquisition of resistance (approximately 16-fold) [54]. This response closely parallels our observations in BRAFV600E melanoma, suggesting that induction of F2RL1 may represent a conserved adaptive response to MAPK pathway inhibition in MAPK-hyperactivated melanoma. Together, these findings support the idea that GPCR-Gαq signaling constitutes a shared mechanism engaged upon BRAFi/MEKi treatment across genetically distinct melanoma subtypes.

Beyond melanoma, our findings suggest broader implications for MAPK-driven malignancies. PAR2 has been implicated in tumor progression in multiple cancer types, including colorectal and breast cancer [55], while Gαq signaling is a well-established oncogenic driver in uveal melanoma through recurrent mutations in GNAQ and GNA11 [43,45]. Together, these observations raise the possibility that GPCR-Gαq-dependent signaling may represent a generalizable mechanism of adaptive MAPK reactivation. Thus, targeting this axis could hold therapeutic potential across diverse cancers that harbor MAPK pathway alterations or exploit similar adaptive resistance programs.

However, several key questions remain. The partial recovery of brood production at 100 μM trametinib in lin-45(V627E) animals may reflect an adaptive resistance mechanism. However, dose-dependent effects of trametinib, U73122, or sotrastaurin on additional targets, as well as indirect effects on reproduction in this genetic background, cannot be excluded. In C. elegans, EGL-30/Gαq also signals through UNC-73/Trio RhoGEF [56]. Although our findings support a contribution of PLC/PKC signaling to trametinib resistance, they do not exclude a contribution from the UNC-73/Trio RhoGEF branch. Whether this branch acts alongside or cooperates with PLC/PKC signaling in resistance remains to be determined. Whether hyperactivation of PKC or other kinase pathways alters trametinib sensitivity in lin-45(V627E) animals also requires further investigation. Future studies will need to investigate the endogenous PAR2 ligands that operate in resistant tumors and explore the contributions of the tumor microenvironment in modulating GPCR-driven resistance pathways. Moreover, functional redundancy among other GPCRs may provide alternative routes to Gαq activation, warranting systematic exploration of alternative resistance networks [53].

In conclusion, our study identifies GPCR-Gαq-PLC-PKC signaling as a conserved and essential mechanism of resistance to MEK inhibition, revealing a therapeutically actionable vulnerability in BRAFV600E melanoma. By leveraging C. elegans as a genetically tractable in vivo discovery platform, we establish a cross-species strategy that enables systematic identification of conserved resistance circuits that may remain obscured in mammalian systems alone. Collectively, our findings provide a rationale for co-targeting MEK and GPCR-Gαq-PLC-PKC signaling as a strategy to overcome acquired resistance and extend the durability of MAPK-directed therapies in patients with MAPK-driven cancers.

Materials and methods

Ethics statement

All animal experiments were approved by the Animal Care and Use Committee of Tsinghua University.

Worm strains and culture

C. elegans were maintained according to the standard methods [57]. All worms were cultivated at 20°C on nematode growth medium (NGM) plates seeded with the Escherichia coli OP50 unless stated otherwise. Adult hermaphrodite worms were used in the live-cell imaging experiments. Bristol N2 was used as the wild-type strain. The alleles used in this study were lin-45(syb4962) IV, encoding LIN-45(V627E); egl-30(cas30009) I, encoding EGL-30(R25C); egl-30(ad806) I, encoding EGL-30(S6F); and egl-30(n686) I, carrying the c.594 − 1G > A splice-acceptor-site variant. The lin-45(syb4962) strain was purchased from SunyBiotech Co., Ltd.; the egl-30(cas30009) allele was isolated through the EMS mutagenesis screen described below; and strains carrying egl-30(ad806) or egl-30(n686) were obtained from the Caenorhabditis Genetics Center (CGC), which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440). Complete strain genotypes and sources are provided in S2 Table.

Genetic screens

We used forward genetic screens to isolate lin-45 (V627E) suppressors. The lin-45 (V627E) mutant animals (P0) were synchronized at the late L4 larval stage, collected in 4 mL M9 buffer, and incubated with 50 mM ethyl methanesulfonate (EMS) for 4 hours at room temperature with constant rotation. Animals were then washed with M9 for three times and cultured under the standard conditions. After 20 hours, adult animals were bleached. Eggs (F1) were distributed and raised on ~800 9-cm NGM plates, each containing 50–100 eggs. Adult F2 animals on each plate were screened for suppression of the Pvl phenotype. F2 animals displaying normal vulval morphology were individually isolated, and their progeny were examined to confirm the heritability of the suppressor phenotype. Whole-genome sequencing identified an R25C substitution in EGL-30; this newly isolated allele was designated egl-30(cas30009). The causal involvement of egl-30 was further supported by introducing two independent loss-of-function alleles, egl-30(ad806) and egl-30(n686), into the lin-45(V627E) background, both of which suppressed the Pvl phenotype.

Brood size assay

For each genotype and treatment condition, approximately 10–30 L4-stage P0 animals were placed on NGM agar plates containing the indicated compound(s) or vehicle control and seeded with Escherichia coli OP50 grown in Luria–Bertani broth. All compounds were added directly to the NGM agar medium at the final concentrations specified in the corresponding figures. P0 animals were allowed to mature and produce F1 progeny on these plates. F1 animals at the L4 stage were randomly selected and individually transferred to fresh OP50-seeded NGM agar plates under the same treatment conditions. Each F1 animal was subsequently transferred every 24 h to a fresh plate under the same treatment conditions until reproduction ceased. Progeny were counted when they reached the L3/L4 stages, and counts across all plates for each F1 animal were summed to determine its total brood size. Total brood sizes were analyzed using Kruskal-Wallis test followed by Dunn’s multiple comparisons test (GraphPad Prism 10). Data are presented as mean ± SD, and p < 0.05 was considered statistically significant. Each data point represents an individual worm, with experiments repeated independently at least three times.

Gonad dissection and oocyte assessment

Day 1 adult C. elegans were transferred to a drop of phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4; pH 7.4) on a glass slide. Each animal was cut near the pharynx with a scalpel to release the gonad. Oocyte morphology was scored in >20 animals per genotype and treatment condition.

RNAi by feeding

RNAi experiments were performed by feeding worms E. coli strain HT115 (DE3) transformed with either the empty vector L4440 as the control or lin-45-targeting constructs. Overnight bacterial culture in LB supplemented with Ampicillin (100 μg / ml) at 37 °C was seeded onto NGM plates containing IPTG (1 mM) and Ampicillin (100 μg / ml) and incubated overnight at room temperature to induce double-stranded RNAs production. L1 larvae were placed on RNAi plates and incubated at 20 °C until adulthood to score phenotypes.

Cell culture and treatment

The human melanoma cell line A375 was a gift from Prof. Jiang Peng (Tsinghua University) and was cultured in DMEM (Gibco) containing 10% fetal bovine serum (Gibco) and 1% penicillin and streptomycin (Yeasen) at 37 ℃ with 5% CO2. A375-TR (A375-trametinib resistant) cell lines were established by culturing parental A375 cells in increasing doses of MEKi trametinib, followed by isolation of individual clones. A375-TR resistant lines were maintained in trametinib (10 nM) > 6 months [48].

Two independent short hairpin RNA (shRNA) constructs, each targeting both human GNAQ and GNA11, and three independent shRNA constructs targeting human F2RL1 were designed and generated via molecular cloning. Five target sequences were used:

shGαq/11#1, 5′-CCGGAGCTCAAGCTGCTGCTGCTCGCTCGAGCGAGCAGCAGCAGCTTGAGCTTTTTTG-3′, shGαq/11#2, 5′-CCGGACCCCTGGTTCCAGAACTCCTCTCGAGAGGAGTTCTGGAACCAGGGGTTTTTTG-3′, shF2RL1#1, 5′-CCGGCGAAACCTCATCTCTACTAAACTCGAGTTTAGTAGAGATGAGGTTTCGTTTTTG-3′, shF2RL1#2, 5′-CCGGGCTCTTTGTAATGTGCTTATTCTCGAGAATAAGCACATTACAAAGAGCTTTTTG-3′, and shF2RL1#3, 5′-CCGGCCACTGTTAAGACCTCCTATTCTCGAGAATAGGAGGTCTTAACAGTGGTTTTTG-3′. A corresponding empty vector was purchased from Sigma-Aldrich and used as a control (Ctrl). Lentiviral particles were produced and used to transduce A375 and A375-TR cells. Following transduction, cells were selected with puromycin (1μg/mL for 4 days) to generate stable polyclonal populations. Cells transduced with the empty-vector control were subjected to the same selection procedure. No single-cell cloning or fluorescence-based sorting was performed for the shRNA-expressing populations. Knockdown efficiency was assessed in the bulk cell populations by immunoblotting before the trametinib-sensitivity assays.

Cell viability assays and combination index calculation

The Cell-ATP Viability Detection Kit (HY-K0302; MedChemExpress) was adopted to determine the Cell viability of each group. Cells were incubated with serial dilutions of drugs alone or two-drug combinations in complete culture medium for 72 h, except that treatment with AZ3451 lasted 96 h. At least three independent experiments were performed. The curve-fitting software, GraphPad Prism version 10 (GraphPad Software, SanDiego, CA, USA), was used to calculate half-maximal inhibitory concentration values. Combination index (CI) values were calculated using the [58] implemented in the synergy Python package [59].

Clonogenic assay

Cells were seeded in six-well plates at low density (100 cells/well) and cultured with drugs for 10 days, after which colonies were fixed with methanol and stained with 1 × crystal violet. The quantification of the average colony area were analysed by using ImageJ.

Mouse xenografts and in vivo drug studies

Female BALB/c-nude mice (5 weeks old) were housed under specific pathogen-free conditions in a temperature-controlled environment (approximately 21 °C) with a 12 h light/12 h dark cycle and ad libitum access to food and water.

For the pharmacological xenograft experiments (Figs 4A-F and 6A–6F), parental A375 or trametinib-resistant A375 (A375-TR) melanoma cells (5 × 10⁶ cells) were resuspended in PBS and injected subcutaneously into the flanks of mice (≥ 5 mice per group). Tumor growth was monitored twice weekly using caliper measurements, and tumor volume was calculated using the modified ellipsoid formula: volume = 1/2 × (length × width2). When the mean tumor volume reached approximately 250 mm3 for parental A375 xenografts or 100–150 mm3 for A375-TR xenografts, mice were randomized into four treatment groups: vehicle control, trametinib alone, PLC/PKC pathway inhibitor alone (U73122 or sotrastaurin), or the combination of trametinib with U73122 or sotrastaurin.

Trametinib (0.2 mg/kg; #C16249920, Macklin) and sotrastaurin (80 mg/kg; #HY-10343, MCE) were formulated in vehicle (5% DMSO, 40% PEG300, 5% Tween-80, and 50% sterile saline, v/v) and administered by oral gavage at a volume of 100 μL per mouse. U73122 (50 mg/kg; #HY-13419, MCE) was ground into fine powder, suspended in sterile saline, and administered by intraperitoneal injection (100 μL per mouse). Treatments were generally performed three times per week. Based on tolerability assessments indicating body weight loss with more frequent dosing, U73122 was administered three times per week in parental A375 xenografts and twice per week in A375-TR xenografts. Control animals received vehicle or sterile saline using the corresponding administration routes and schedules.

For the shGαq/11 xenograft experiments (Fig 6G-I), A375-TR cells stably expressing shGαq/11#2 or the corresponding control vector (Ctrl) were used. Cells (5 × 10⁶) were resuspended in PBS and injected subcutaneously into the flanks of female BALB/c-nude mice. Tumor growth was monitored three times per week by caliper measurements, and tumor volume was calculated using the modified ellipsoid formula described above. When the mean tumor volume reached approximately 150–250 mm3, mice within each of the Ctrl and shGαq/11#2 groups were randomly assigned to receive either vehicle or trametinib treatment. Trametinib was administered at 0.2 mg/kg by oral gavage three times per week, as described above, and control mice received the corresponding vehicle on the same schedule.

Mouse body weight and general condition were monitored throughout the treatment period.

Western blot analysis

Cells were washed three times with ice-cold phosphate-buffered saline (PBS) to remove residual medium and debris, and lysed in RIPA buffer (#C0121, Beyotime) supplemented with complete protease inhibitors and PhosSTOP phosphatase inhibitors (Roche). Lysates were clarified by centrifugation at 14,000 × g for 15 min at 4 °C, and supernatants were collected and stored at -80 °C until use. Protein samples were mixed with 5 × SDS loading buffer (#20315ES20, Yeasen), boiled at 95 °C for 5 min, and resolved by SDS-PAGE using FastPAGE precast gels (#TSP024–15, TSINGKE). Proteins were transferred onto PVDF membranes (#B36011, ESAYBIO), which were blocked in 5% bovine serum albumin (BSA) and incubated with primary antibodies overnight at 4 °C.

After washing three times with TBST (TBS containing 0.1% Tween-20; #T1081, Solarbio), membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Immunoreactive bands were detected using SuperSignal West Dura chemiluminescent substrate (Thermo Fisher Scientific, #34076).

The following antibodies were used: anti-α-tubulin (DM1A; #3873T, CST), anti-Gαq (D5V1B; #14373S, CST), anti-GNA11 (ActivAb Anti-GNA11 polyclonal antibody; #K003471P, Solarbio), anti-PAR2 (D61D5; #6976, CST), anti-ERK1/2 (p44/42 MAPK; #4695T, CST), and anti-phospho-ERK1/2 (Thr202/Tyr204; #4370T, CST). HRP-linked anti-mouse (#7076P2, CST) and anti-rabbit (#7074P2, CST) IgG antibodies were used as secondary antibodies.

RNA sequencing

Synchronized worms were cultured on NGM plates with the OP50 bacteria. Day 1 adult worms were harvested 24 hours after the fourth larval (L4) stage and then lysed with TRIzol reagent (Invitrogen). For cell lines, after treatment with serial dilutions of drugs in complete culture medium for 24 h, A375 or A375-TR cells were lysed with TRIzol reagent (Invitrogen). Total RNA was extracted according to the manufacturer’s protocol. SUPERase•In RNase Inhibitor (Invitrogen) was used in each step to prevent RNA from degradation. RNA concentration was quantified using the Qubit RNA High Sensitivity Assay Kit (Invitrogen). RNA quality was assessed with the Agilent 2100 bioanalyzer system, and samples with an RNA integrity number (RIN) above 6.0 were used to construct the library, 50 ng to 500 ng of total RNA was used for library preparation using the KAPA RNA HyperPrep Kit (KAPA Biosystems). Library samples were analyzed by Agilent 2100 bioanalyzer system and Qubit for quality control and quantification. The samples were sequenced on an Illumina HiSeq platform. A total of 150-bp paired-end reads were generated.

Gene expression analysis

For C. elegans RNA-seq data, raw reads were assessed for sequence quality, adapter content, and duplication rates using FastQC. Low-quality bases and adapter sequences were removed using Trim Galore (version 0.4.4). Paired-end reads at least 20 nucleotides in length were aligned to the C. elegans reference genome (ce10) using STAR (version 2.5.4b), with the sjdbOverhang parameter set to 139. Read counts were quantified using HTSeq (version 0.9.1). Only uniquely mapped reads were included; reads overlapping multiple genes or mapping to multiple genomic locations were excluded. Gene names were annotated using DAVID (https://david.ncifcrf.gov/).

For human RNA-seq data, paired-end reads from parental A375 and trametinib-resistant A375-TR cells were aligned to the human reference genome (hg38) using HISAT2. The resulting SAM files were converted to BAM format and sorted using SAMtools. Gene-level read counts were quantified using featureCounts with the human gene annotation corresponding to hg38. Reads overlapping exons were assigned to genes based on the gene_id attribute, and the -p option was enabled for paired-end sequencing data.

For both datasets, differential expression analysis was performed using DESeq2 in R, with unnormalized counts generated by HTSeq and featureCounts for the C. elegans and human datasets, respectively. Differentially expressed genes were defined by a false discovery rate (FDR) < 0.05, an absolute log2 fold change > 1, and unnormalized counts from HTSeq > 3. Genes meeting these criteria were classified as upregulated or downregulated according to whether their log2 fold change was > 1 or <−1, respectively. For the human comparison, fold changes were calculated for A375-TR cells relative to parental A375 cells. Figures were generated using ggplot2 in R.

Molecular biology

Short hairpin RNAs (shRNAs) targeting GNA11, GNAQ and F2RL1 were designed based on published sequences. Oligonucleotides encoding the hairpin sequences were synthesized, annealed, and cloned into the vector pLKO.1 plasmid downstream of the U6 promoter via standard molecular cloning techniques following standard protocols. Ligated products were transformed into E. coli DH5α, and positive clones were confirmed by colony PCR and Sanger sequencing. All the plasmids and primers were listed in S3 Table.

Imaging

Adult C. elegans hermaphrodites were anesthetized using 1 μM levamisole in M9 buffer, mounted on 3% agarose pads, maintained at room temperature and imaged immediately. A Zeiss LSM900 confocal microscope equipped with a 100 × /1.46 oil objective and controlled by ZEN software (Carl Zeiss) was utilized. All images were acquired using a Zeiss Axio Observer (bright-field mode).

Supporting information

S1 Fig. Conservation of the BRAF/LIN-45 activation-loop valine and characterization of lin-45(V627E) animals.

(A) Multiple sequence alignment of C. elegans LIN-45 and its homologs in human (Homo sapiens, Hs), mouse (Mus musculus, Mm), and zebrafish (Danio rerio, Dr). The arrow indicates the conserved valine residue in the activation loop, whose substitution by glutamate (V627E) mimics phosphorylation and confers constitutive kinase activation. (B) Representative bright-field images of oocyte morphology in day 1 adult WT and lin-45(V627E) animals treated with DMSO or trametinib (Tram) at the indicated concentrations. Red arrows indicate enlarged oocyte-like compartments, and black arrowheads indicate their visible boundaries. Percentages indicate the proportion of animals displaying the indicated oocyte phenotype. Scale bar, 50 μm. (C) Quantification of the oocyte phenotypes shown in (B). The exact numbers of animals examined are shown in parentheses below the corresponding genotype labels. Phenotype distributions were compared between genotypes under each treatment condition using two-sided exact tests: Fisher’s exact test was used for 2 × 2 contingency tables, and the Fisher–Freeman–Halton exact test was used for the 2 × 3 contingency table at 1 μM. P values were adjusted using the Holm method. ****P < 0.0001; ns, not significant. (D) Representative bright-field images of vulval morphology in day 1 adult WT and lin-45(V627E) animals treated with Tram at the indicated concentrations. Dashed boxes indicate the vulval region. The corresponding quantification and statistical analysis are shown in Fig 1D. Scale bar, 10 μm.

(TIF)

pgen.1012373.s001.tif (8.7MB, tif)
S2 Fig. Upregulation of egl-30/Gαq and contribution of PLC-PKC signaling to high-dose trametinib resistance in lin-45(V627E) mutants.

(A) Principal component analysis (PCA) of RNA-seq profiles from lin-45(V627E) F1 animals treated with 100 μM or 10 μM trametinib (n = 3 independent biological replicates per condition). (B) Integrative Genomics Viewer (IGV) tracks showing normalized RNA-seq read coverage at the egl-30 locus in lin-45(V627E) F1 animals treated with 100 μM or 10 μM trametinib. (C) Representative bright-field images of wild-type (WT) and lin-45(V627E) animals, along with their progeny, following treatment with DMSO or trametinib (Tram) at the indicated concentrations for 10 days. Five adult animals were transferred per plate. Scale bar, 1 mm. (D) Schematic representation of Gαq–PLC–PKC signaling and the canonical RAS–RAF–MEK–ERK cascade as distinct but potentially interacting pathways regulating fertility. Solid arrows indicate established signaling relationships, whereas dashed arrows indicate possible pathway crosstalk or MAPK-independent contributions to fertility. The molecular targets of U73122, sotrastaurin (Sotra), and trametinib (Tram) are indicated. (E) Representative bright-field images of lin-45(V627E) animals along with their progeny, following treatment with DMSO, trametinib (100 μM), U73122 (50 μM), sotrastaurin (50 μM), or the indicated drug combinations for 10 days. Scale bar, 1 mm.

(TIF)

pgen.1012373.s002.tif (10.3MB, tif)
S3 Fig. Inhibition of Gαq-PLC-PKC signaling reduces clonogenic growth of parental A375 cells.

(A) Colony formation assay of A375 cells transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib at the indicated concentrations. Representative images of crystal violet-stained colonies (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (B) Colony formation assay of A375 cells treated with vehicle, trametinib (1 nM), U73122 (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates. (C) Colony formation assay of A375 cells treated with vehicle, trametinib (1 nM), sotrastaurin (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates.

(TIF)

pgen.1012373.s003.tif (3.1MB, tif)
S4 Fig. Body weight monitoring of A375 xenograft-bearing mice during treatment.

(A) Body weights of parental A375 xenograft-bearing mice treated with vehicle, U73122 (50 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 17 mice per group). (B) Body weights of parental A375 xenograft-bearing mice treated with vehicle, sotrastaurin (Sotra; 80 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 12 mice per group). Data represent mean ± SEM. Treatments were initiated when mean tumor volume reached ~250 mm3.

(TIF)

S5 Fig. Inhibition of Gαq-PLC-PKC signaling reduces clonogenic growth of trametinib-resistant A375 cells.

(A) Colony formation assay of parental A375 and trametinib-resistant A375 (A375-TR) cells treated with vehicle or trametinib at the indicated concentrations. Representative images of crystal violet-stained colonies (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (B) Colony formation assay of A375-TR cells transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib at the indicated concentrations. Representative images (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (C) Colony formation assay of A375-TR cells treated with vehicle, trametinib (1 nM), U73122 (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates. (D) Colony formation assay of A375-TR cells treated with vehicle, trametinib (1 nM), sotrastaurin (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, **P < 0.01, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates.

(TIF)

pgen.1012373.s005.tif (4.2MB, tif)
S6 Fig. Body weight monitoring of A375-TR xenograft-bearing mice during treatment.

(A) Body weights of trametinib-resistant A375-TR xenograft-bearing mice treated with vehicle, U73122 (50 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 10 mice per group). (B) Body weights of A375-TR xenograft-bearing mice treated with vehicle, sotrastaurin (80 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 10 mice per group). (C) Body weights of mice bearing A375-TR xenografts transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib (0.2 mg/kg) (n = 18 mice per group). Data represent mean ± SEM.

(TIF)

pgen.1012373.s006.tif (1.2MB, tif)
S7 Fig. Dataset-specific expression changes of F2RL1 (PAR2), GNAQ, and GNA11 in melanoma samples before and after MAPK pathway inhibitor treatment.

(A-C) Paired human melanoma samples from individual datasets (RNA-seq: 50535 and 77940; microarray: 50509 and 61992) were analyzed for F2RL1 (PAR2), GNAQ, and GNA11 mRNA levels pre-/post-treatment with BRAFi, MEKi, or combined BRAFi/MEKi. Numbers in each column indicate the number of sample pairs.

(TIF)

pgen.1012373.s007.tif (1.5MB, tif)
S1 Table. RNA-seq analysis of Gαq-associated genes in lin-45(V627E) animals (100 vs. 10 μM trametinib).

Differentially expressed Gαq-associated genes identified by RNA-seq in lin-45(V627E) animals treated with 100 or 10 μM trametinib.

(XLSX)

pgen.1012373.s008.xlsx (10.6KB, xlsx)
S2 Table. Caenorhabditis elegans strains used in this study.

Genotypes and descriptions of all C. elegans strains used in this work.

(XLSX)

pgen.1012373.s009.xlsx (10KB, xlsx)
S3 Table. Plasmids and primers used in this study.

Plasmids and shRNA oligonucleotide sequences used for gene knockdown in cultured cells.

(XLSX)

pgen.1012373.s010.xlsx (10.2KB, xlsx)
S1. Rawgel.

Uncropped gel images for western blots presented in this study.

(PDF)

pgen.1012373.s011.pdf (14.4MB, pdf)

Acknowledgments

We thank Prof. Stephan Vagner and Prof. Peng Jiang for valuable discussions and insightful comments on the manuscript.

Data Availability

Data and materials availability: All data are available in the main text or supplementary materials. All sequencing data from this study have been submitted to the NCBI Sequence Read Archive (SRA; www.ncbi.nlm.nih.gov/sra) with BioProject accession numbers PRJNA1404971 and PRJNA1405274.

Funding Statement

W.L. received funding from the National Key R&D Program of China (Grant Nos. 2022YFA1302700 and 2024YFA1307301) and the National Natural Science Foundation of China (Grant Nos. 32270773 and 32470730). G.O. received funding from the National Natural Science Foundation of China (Grant Nos. 92254306, 32021002, and 32430026) and the TsienTang Life Science Development Fund at Tsinghua University. National Key R&D Program of China: https://service.most.gov.cn National Natural Science Foundation of China: https://www.nsfc.gov.cn The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. 2018. Melanoma. Lancet. 392:971–84. [DOI] [PubMed] [Google Scholar]
  • 2.Centeno PP, Pavet V, Marais R. The journey from melanocytes to melanoma. Nat Rev Cancer. 2023;23(6):372–90. doi: 10.1038/s41568-023-00565-7 [DOI] [PubMed] [Google Scholar]
  • 3.Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. doi: 10.1038/nature00766 [DOI] [PubMed] [Google Scholar]
  • 4.Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67. doi: 10.1016/s0092-8674(04)00215-6 [DOI] [PubMed] [Google Scholar]
  • 5.Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer. 2012;12(5):349–61. doi: 10.1038/nrc3218 [DOI] [PubMed] [Google Scholar]
  • 6.Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14. doi: 10.1056/NEJMoa1203421 [DOI] [PubMed] [Google Scholar]
  • 7.Halle BR, Johnson DB. Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol. 2021;22(4):30. doi: 10.1007/s11864-021-00827-2 [DOI] [PubMed] [Google Scholar]
  • 8.Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. doi: 10.1016/S1470-2045(18)30142-6 [DOI] [PubMed] [Google Scholar]
  • 9.Cohen JV, Sullivan RJ. Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma. Clin Cancer Res. 2019;25(19):5735–42. doi: 10.1158/1078-0432.CCR-18-0836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Adashek JJ, Menta AK, Reddy NK, Desai AP, Roszik J, Subbiah V. Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600-mutant tumors. Mol Cancer Ther. 2022;21(6):871–8. doi: 10.1158/1535-7163.MCT-21-0950 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095–107. doi: 10.2147/OTT.S182721 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hartman ML, Sztiller-Sikorska M, Gajos-Michniewicz A, Czyz M. Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity. Cells-Basel. 2020;9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, et al. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol. 2014;25(5):959–67. doi: 10.1093/annonc/mdu049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sternberg PW, Han M. Genetics of RAS signaling in C. elegans. Trends Genet. 1998;14(11):466–72. doi: 10.1016/s0168-9525(98)01592-3 [DOI] [PubMed] [Google Scholar]
  • 15.Han M, Sternberg PW. Let-60, a gene that specifies cell fates during C. elegans vulval induction, encodes a ras protein. Cell. 1990;63(5):921–31. doi: 10.1016/0092-8674(90)90495-z [DOI] [PubMed] [Google Scholar]
  • 16.Han M, Golden A, Han YM, Sternberg PW. C-elegans lin-45 raf gene participates in let-60 ras-stimulated vulvar differentiation. Nature. 1993;363:133–40. [DOI] [PubMed] [Google Scholar]
  • 17.Lackner MR, Kornfeld K, Miller LM, Horvitz HR, Kim SK. A MAP kinase homolog, mpk-1, is involved in ras-mediated induction of vulval cell fates in Caenorhabditis elegans. Genes Dev. 1994;8(2):160–73. doi: 10.1101/gad.8.2.160 [DOI] [PubMed] [Google Scholar]
  • 18.Wu Y, Han M, Guan KL. MEK-2, a Caenorhabditis elegans MAP kinase kinase, functions in Ras-mediated vulval induction and other developmental events. Genes Dev. 1995;9(6):742–55. doi: 10.1101/gad.9.6.742 [DOI] [PubMed] [Google Scholar]
  • 19.Lackner MR, Kim SK. Genetic analysis of the MAP kinase gene. Genetics. 1998;150:103–17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hsu V, Zobel CL, Lambie EJ, Schedl T, Kornfeld K. Caenorhabditis elegans lin-45 raf is essential for larval viability, fertility and the induction of vulval cell fates. Genetics. 2002;160(2):481–92. doi: 10.1093/genetics/160.2.481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sundaram MV. Canonical RTK-Ras-ERK signaling and related alternative pathways. WormBook. 2013;1–38. doi: 10.1895/wormbook.1.80.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hara M, Han M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci USA. 1995;92(8):3333–7. doi: 10.1073/pnas.92.8.3333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bae YK, Sung JY, Kim YN, Kim S, Hong KM, Kim HT, et al. An model system for screening EGFR-inhibiting anti-cancer drugs. PLoS One. 2012;7(9):e42441. doi: 10.1371/journal.pone.0042441 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ji JJ, Yuan J, Guo XY, Ji RF, Quan QH, Ding M, et al. Harmine suppresses hyper-activated Ras-MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans. Cancer Cell Int. 2019;19:159. doi: 10.1186/s12935-019-0880-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gorgoń S, Billing O, Eriksson AU, Hemmingsson O. A drug discovery pipeline for MAPK/ERK pathway inhibitors in Caenorhabditis elegans. Cancer Res Commun. 2024;4(9):2454–62. doi: 10.1158/2767-9764.CRC-24-0221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Church DL, Guan KL, Lambie EJ. 3 genes of the map kinase cascade, Mek-2, Mpk-1/Sur-1 and Let-60 Ras, are required for meiotic cell-cycle progression in Caenorhabditis elegans. Development. 1995;121:2525–35. [DOI] [PubMed] [Google Scholar]
  • 27.Hajnal A, Berset T. The C. elegans MAPK phosphatase LIP-1 is required for the G(2)/M meiotic arrest of developing oocytes. EMBO J. 2002;21(16):4317–26. doi: 10.1093/emboj/cdf430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Rebecca VW, Somasundaram R. Nongenetic mechanisms of drug resistance in Melanoma. Annu Rev Cancer Biol. 2020;4(1):315–30. doi: 10.1146/annurev-cancerbio-030419-033533 [DOI] [Google Scholar]
  • 29.Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750–60. doi: 10.1158/0008-5472.CAN-10-2954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018;24(2):203–12. doi: 10.1038/nm.4472 [DOI] [PubMed] [Google Scholar]
  • 31.Tripathi R, Liu Z, Jain A, Lyon A, Meeks C, Richards D, et al. Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling. Nat Commun. 2020;11(1):5463. doi: 10.1038/s41467-020-19075-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014;513(7516):105–9. doi: 10.1038/nature13572 [DOI] [PubMed] [Google Scholar]
  • 33.Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–7. doi: 10.1038/nature09626 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Res. 2014;74(23):7037–47. doi: 10.1158/0008-5472.CAN-14-1392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118–22. doi: 10.1038/nature13121 [DOI] [PubMed] [Google Scholar]
  • 36.Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, et al. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma. Nat Commun. 2018;9(1):28. doi: 10.1038/s41467-017-02354-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7(2):79–94. doi: 10.1038/nrc2069 [DOI] [PubMed] [Google Scholar]
  • 38.O'Hayre M, Degese MS, Gutkind JS. 2014. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr Opin Cell Biol. 27:126–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Stagg J, Gutkind JS. 2025. Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies. Annu Rev Pharmacol Toxicol. 65:315–31. [DOI] [PubMed] [Google Scholar]
  • 40.Kawaguchi M, Yamamoto K, Kataoka H, Izumi A, Yamashita F, Kiwaki T, et al. Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-κB signaling and tumor angiogenesis in ApcMin/+ mice. Cancer Sci. 2020;111(4):1193–202. doi: 10.1111/cas.14335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bhansali D, Tu NH, Inoue K, Teng S, Li T, Tran HD, et al. PAR(2) on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451. Biomaterials. 2025;314:122874. doi: 10.1016/j.biomaterials.2024.122874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Dai Y, Li C, Cheng S, Wang H, Zhuang X. Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis. Sci Rep. 2025;15(1):5228. doi: 10.1038/s41598-025-89746-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2014;33(39):4724–34. doi: 10.1038/onc.2013.418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Maziarz M, Leyme A, Marivin A, Luebbers A, Patel PP, Chen Z, et al. Atypical activation of the G protein Gαq by the oncogenic mutation Q209P. J Biol Chem. 2018;293(51):19586–99. doi: 10.1074/jbc.RA118.005291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Hitchman TD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, et al. Combined inhibition of Gαq and MEK enhances therapeutic efficacy in Uveal Melanoma. Clin Cancer Res. 2021;27(5):1476–90. doi: 10.1158/1078-0432.CCR-20-2860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ma J, Weng L, Bastian BC, Chen X. Functional characterization of uveal melanoma oncogenes. Oncogene. 2021;40(4):806–20. doi: 10.1038/s41388-020-01569-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hubbard KB, Hepler JR. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal. 2006;18(2):135–50. doi: 10.1016/j.cellsig.2005.08.004 [DOI] [PubMed] [Google Scholar]
  • 48.Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–95. doi: 10.1016/j.ccr.2010.11.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014;5:5694. doi: 10.1038/ncomms6694 [DOI] [PubMed] [Google Scholar]
  • 50.Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965–77. doi: 10.1158/1078-0432.CCR-13-3122 [DOI] [PubMed] [Google Scholar]
  • 51.Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4(1):61–8. doi: 10.1158/2159-8290.CD-13-0631 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–96. doi: 10.1126/science.aad0501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Adams MN, Ramachandran R, Yau M-K, Suen JY, Fairlie DP, Hollenberg MD, et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011;130(3):248–82. doi: 10.1016/j.pharmthera.2011.01.003 [DOI] [PubMed] [Google Scholar]
  • 54.Dinter L, Karitzky PC, Schulz A, Wurm AA, Mehnert M-C, Sergon M, et al. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. Int J Cancer. 2024;154(6):1057–72. doi: 10.1002/ijc.34807 [DOI] [PubMed] [Google Scholar]
  • 55.Chaudhary PK, Kim S. An insight into GPCR and G-proteins as cancer drivers. Cells. 2021;10(12):3288. doi: 10.3390/cells10123288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Williams SL, Lutz S, Charlie NK, Vettel C, Ailion M, Coco C, et al. Trio’s Rho-specific GEF domain is the missing Galpha q effector in C. elegans. Genes Dev. 2007;21(21):2731–46. doi: 10.1101/gad.1592007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77(1):71–94. doi: 10.1093/genetics/77.1.71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4 [DOI] [PubMed] [Google Scholar]
  • 59.Wooten DJ, Albert R. synergy: A Python library for calculating, analyzing and visualizing drug combination synergy. Bioinformatics. 2021;37(10):1473–4. doi: 10.1093/bioinformatics/btaa826 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Kent W Hunter, Bruce E Clurman

21 Aug 2026

PGENETICS-D-26-00705

GPCR-Gαq Signaling Drives Adaptive Resistance to MEK Inhibition in BRAF-Mutant Melanoma

PLOS Genetics

Dear Dr. Ke,

Thank you for submitting your manuscript to PLOS Genetics. After careful consideration, we feel that it has merit but does not fully meet PLOS Genetics's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 20 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosgenetics@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgenetics/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Bruce E. Clurman

Academic Editor

PLOS Genetics

Kent Hunter

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

Additional Editor Comments (if provided):

Your paper was comprehensively reviewed by tw experts in the field, who found many strengths, but also some areas where more work is needed. This is particular true regarding some of the C/ elegant work. There are also many detailed comments regarding data presentation and consistency in results across different experiments and figures.

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

1) We do not publish any copyright or trademark symbols that usually accompany proprietary names, eg ©,  ®, or TM  (e.g. next to drug or reagent names). Therefore please remove all instances of trademark/copyright symbols throughout the text, including:

- TM on page: 20.

2) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines:

https://journals.plos.org/plosgenetics/s/figures

3) Please upload a copy of Figure Fig 1-7 which you refer to in your text on pages 7, 8, 9, 10, and 11. Or, if the figure is no longer to be included as part of the submission please remove all reference to it within the text.

4) Please send a completed 'Competing Interests' statement, including any COIs declared by your co-authors. If you have no competing interests to declare, please state "The authors have declared that no competing interests exist". Otherwise please declare all competing interests beginning with the statement "I have read the journal's policy and the authors of this manuscript have the following competing interests:"

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Summary:

This work by Ke et al shows that GPCR-Galphaq-PLCbeta-PKC signaling contributes to oncogenic Raf signaling and adaptive resistance to a MEK inhibitor in human and nematode cells. Adaptive resistance to MEK inhibitors is primarily a non-genetic process, likely involving changes such as negative feedback and pathway rewiring, that allow cancer cells to tolerate an inhibitor. For this work, the authors use a Caenorhabditis elegans model of the oncogenic BRAF(V600E) mutation, and they show that this mutant -- termed lin-45(V627E) -- is resistant to phenotypes caused by the MEK inhibitor Trametinib. Using the C. elegans model, they discover that loss of the worm ortholog of G protein subunit alpha Q (Galphaq) restores drug sensitivity. Moving to human melanoma cells carrying the BRAF(V600E) mutation, this work tests phospho-ERK levels, cell viability, and xenograft growth in the presence of Trametinib, showing that knockdown or drug inhibition of human GNAQ and GNA11 sensitizes cells to this drug. Importantly, this work also shows that inhibition of either Galphaq or the G protein coupled receptor F2RL1 is effective at sensitizing melanoma that had previously acquired Trametinib drug resistance.

Strengths:

1. The work is of high interest to investigators in the fields of cancer biology and cell signaling.

2. Although previous studies have shown that Galphaq signaling can activate ERK, this work is highly interesting because it demonstrates therapeutic potential for a combination treatment using both MEK and Galphaq inhibitors.

3. This work suggests evolutionary conservation of a requirement for Galphaq in Raf signaling. Furthermore, if some evidence is strengthened (see my comments), this work might establish a C. elegans model as a discovery/testing platform for Raf inhibitors.

Major comments:

My major concerns are about the C. elegans experiments, which I felt were underdeveloped with regard to the effects of Trametinib and establishing the Raf/lin-45 gene as causative for some phenotypes. I don't believe these issues detract from the human cell evidence. However, as the manuscript may provide a C. elegans model for further work on Raf inhibitors, I think it's important to strengthen these data.

1. In C. elegans, treatment of wild-type and lin-45(V627E) animals with Trametinib caused a reduction in brood size (Fig. 1).

My concern is that disruption of many different cell signals can reduce brood size. An additional complication is that either increase or decrease in Raf activity results in sterility. To distinguish between these possibilities, I would expect this work to include phenotype scoring for specific germline phenotypes. For example, increased Ras/let-60 activity is known to cause premature progression through the pachytene phase and produce small, stacked oocytes. Conversely, decreased ERK/mpk-1 activity causes an arrest in the pachytene phase and giant oocytes. Examples of these phenotype can be found in Lee, et al. 2007.

2. A new finding in this work is that C. elegans animals with the lin-45(V627E) mutation display a protruding vulva phenotype (Fig. 1, Fig. 2, Fig. S1).

My concern is that in C. elegans, the protruding vulva phenotype -- in contrast to the Multivulva phenotype -- is not a very well-characterized consequence of Raf gain of function. For this reason, it is important to demonstrate a gene-phenotype relationship. (I don’t consider suppression by Trametinib to establish this because drugs may have off-target effects.) There are several ways to do this. I would encourage the authors to either test a second, independently generated lin-45 gain-of-function allele, or alternatively, test whether reducing lin-45 activity reverts the phenotype to normal. There is a second published, independent lin-45(V627E) gene-edit allele generated by Billing, et al. 2021.

Minor comments:

1. The exact procedure used for treatment of C. elegans with Trametinib was not included in the Methods text. My concern is that treatment of C. elegans with chemicals is notoriously difficult/ineffective. Fig. 1A implies that the P0 animal was treated but does not indicate the concentration used. Fig. 1A shows that the F1 animal tested for fertility was treated, but not how. For example, was the drug added to liquid culture or to agar plates?

2. I thank the authors for including a table of C. elegans strains and genotypes in the supplement. I would encourage them to list C. elegans alleles used in the main text Methods as well.

Works cited in my comments:

Lee MH, Ohmachi M, Arur S, Nayak S, Francis R, Church D, Lambie E, Schedl T. Multiple functions and dynamic activation of MPK-1 extracellular signal-regulated kinase signaling in Caenorhabditis elegans germline development. Genetics. 2007 Dec;177(4):2039-62. doi: 10.1534/genetics.107.081356.

Billing O, Holmgren Y, Nosek D, Hedman H, Hemmingsson O. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene. 2021 May;40(21):3707-3718. doi: 10.1038/s41388-021-01808-3.

Reviewer #2: This paper explores the mechanisms of adaptive resistance to the MEK inhibitor Trametinib (Tram) downstream of the Raf oncogene using a combination of the C. elegans animal model, a cultured cell model of melanoma, and xenografts in mice. The authors start by building a strain that bears the V627E mutant of C. elegans Raf (LIN-45) that mimics the human BRAFV600E oncogenic mutation associated with human melanoma. The authors then test whether these strains show altered sensitivity to Tram that might be expected if Raf signaling through the MEK pathway is genetically elevated. Using fertility as a readout, the authors find animals with V627E Raf show a change in Tram sensitivity, with V627E Raf animals showing similar ‘sterility’ resistance at low (1 µM) or high (100 µM Tram concentrations. However, animals were still sensitive to intermediate (10 µM) Tram levels for reasons that are not clearly explained beyond the authors invocation of adaptation. The authors also looked at vulval development which was also affected by Tram and V627E Raf although whether and how these vulval phenotypes relate to the observed effects of Tram are not well connected in the written Results.

The authors continue using the C. elegans system to understand how V627E Raf affects gene expression, finding changes in Gq (egl-30) RNA expression. The authors do not report the degree to which other Gq signaling componets (e.g. eat-16, egl-8, unc-73) also show changes in gene expression which would presumably help inform whether the egl-30 result is unique or tied to canonical Gq effectors. Regardless, in a separate genetic screen for suppressors of the V627E Raf protruding vulva, the authors identified loss-of-function egl-30 mutations, suggesting Gq signaling is required. The authors find that Gq suppressor mutations also restore Tram sensitivity, although whether this is caused by a bona fide increase in MEK signaling that then has renewed sensitivity to Tram vs. synthetic or indirect effects on brood size are not entirely clear. However, the authors find that chemical inhibition of PLC or PKC signaling phenocopies the effects on Tram sensitivity.

The authors then explore the relationship between PAR2/Gq/G11 signaling in Tram sensitivity in the A375 melanoma cell culture, A375-TR and tumor xenograft models, using knockdown and pharmacological approaches to manipulate signaling. The authors find largely consistent results that manipulation of Gq signaling affects Tram sensitivity and vice versa.

Overall, the experiments are well-controlled and interpreted. The key result is the connection between Gq and MEK signaling and the alteration of Tram and other drug responses although the mechanism(s) remain unclear, including whether / how MEK inhibition (or Raf oncogenic mutation) affects signaling directly, gene expression, or both. The cartoon in Figure 2G suggesting all the molecules act within the same biochemical pathway which would not necessarily explain some of the synergistic phenotypes observed. Such epistasis experiments would suggest the Gq and MEK pathways are parallel, and the authors should try to address in the text possible biochemical mechanisms and whether they suggest parallel pre-existing signaling or mechanisms newly induced upon pathway hyperactivation / disruption in cancer.

Concerns / comments:

- Does the resistance to high Tram concentrations indicate an adaptive resistance phenotype or the sensitivity of another factor to inhibition? That is, is there another target for Tram or the other drugs that is only revealed in these specific, sensitized cases?

- In Figure 2, are other components of the Gq signaling pathway upregulated? Could a list of genes and where egl-30 is placed be included as part of the manuscript? I realize accession numbers for the RNAseq data have been posted to NCBI, but it might be helpful to verify whether other G protein signaling components (e.g. unc-73 and egl-8) or other targets of PLC inhibitors were similarly upregulated (or not).

- How are brood sizes affected in the absence of 100 µM Trametinib? Specifically, you see a dramatic reduction in brood size by the egl-30(R25C) mutation, but is this a unique effect of Tram treatment or is this observed even in the absence of the drug? Loss of egl-30 can lead a larval arrest phenotype or egg-laying defects, so it is hard to know if you can directly correlate the loss of egl-30 to a Tram-specific phenotype unless it is not observed without it. Do mutations that affect egl-30 affect Tram sensitivity on their own?

- The authors use U73122 to inhibit PLC-beta, but I think U73122 is through to be a more general inhibitor of PLCs of which there are other in C. elegans that might affect fertility downstream of egl-30 signaling. Consider describing this pathway downstream of Gq as PLC/PKC.

Egl-30 is also thought to signal through Trio RhoGEF. Can the authors speculate whether the Trio RhoGEF pathway is decidedly not involved?

Phorbol esters activate PKC signaling, could the authors test whether hyperactivation of the PKC pathway or other kinase pathways affects (enhances?) lin-45(V627E) sensitivity?

- In Figure 3B, the authors report a modest but significant change in Tram drug sensitivity upon Gq or G11 knockdown. This occurs over a rather narrow window of Tram efficacy, although whether this relates to heterogeneity in protein knockdown across the cell population or within individual cells is not clear. Details on whether / how transgenic cells were identified (or not) might inform whether this is a case of transfection efficiency.

- I wish there was more alignment in the labeling of data presented in Figure 3E as the dose-response curves have different units than the combination index heat map, specifically the use of fM in the curve and 5 to -3 log10 (nM) in the heat map. I cannot easily tell if there is a 1:1 relationship to the points shown between the left and right panels.

- Does the fact that Tram and the PLC and PKC inhibitors show additive effects suggest they act along different pathways? You might expect that sufficient inhibition of one pathway would reduce the efficacy of the other. You certainly would not expect a concentration of inhibitor that acts in an intermediate fashion (e.g. stronger effect at lower and higher concentrations) particularly in cultured cells where presumably effects are more acute. Some more explanation on the mechanisms though to be at work here would help. As it is, I am not sure one could clearly state that alteration of Gq/G11 signaling affected Tram efficacy since those genetic manipulations already affect the degree of pERK phosphorylation.

- In Figure 5C: what specific conditions are begin quantified here? The degree of difference is not expected if just between DMSO and 0 nM Tram, but maybe it’s the fraction of Tram inhibition w/ DMSO set to 1? The legend could be improved to clarify where these bars come from.

Same recommendation for help in clarifying alignment between 5H and 5I.

- Hard to be sure drugs like Sotra and U73122 act within the tumor vs. the animal. Gq/11 knockdowns are more easily interpreted as a result. It might be helpful to discuss this limitation.

- Are differences in Figure 7A statistically significant (e.g. by chi-square test)? Is there a cutoff for what would count as ‘no change’ in gene expression in these patients (e.g. non-statistically difference), or are they automatically binned into increased vs. decreased? If so, this may be misleading to then state “Consistent with patient data, the GPCR F2RL1 was *robustly* upregulated in resistant cells compared to parental controls” (emphasis added). That would not be my interpretation of the data in Figure 7A.

- Figure 7F (well, the panels below) should have additional labeling on the x axis as to what the concentrations shown indicate. The colors are a little confusing, being used for different shR2RL1 knockdowns vs. dose response of AZ3451.

- Why is Tram so much less effective on A375-TR cells shown in Figure 7E experiment compared to Figure 5A? Does this affect any interpretations of restoration of drug efficacy?

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics  data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: No:  Genomic data has been submitted and is available. I did not see raw data from graphs and summary statistics included in the supplement. It was also not mentioned as being available on 3rd party sharing sites like FigShare, etc.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Kent W Hunter, Bruce E Clurman

22 Oct 2026

PGENETICS-D-26-00705R1

GPCR-Gαq Signaling Drives Adaptive Resistance to MEK Inhibition in BRAF-Mutant Melanoma

PLOS Genetics

Dear Dr. Ke,

Thank you for submitting your manuscript to PLOS Genetics. After careful consideration, we feel that it has merit but does not fully meet PLOS Genetics's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript within by Nov 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosgenetics@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgenetics/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to formatting updates and technical items listed in the 'Journal Requirements' section below.

* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Bruce E. Clurman

Academic Editor

PLOS Genetics

Kent Hunter

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

Additional Editor Comments (if provided):

Your revision is nearly ready fro acceptance, As last point, please response to Rev1's comments in point 1, and qualify the conclusions a bit around the shared phenotypes. It's your decision ii you want to move the supp. figure into the main figures as suggested.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Summary:

This work by Ke et al shows that GPCR-Galphaq-PLCbeta-PKC signaling contributes to oncogenic Raf signaling and adaptive resistance to a MEK inhibitor in human and nematode cells. In this resubmission, the authors present new data in an effort to address two of my concerns raised in review.

Comments:

1. Previously, I asked whether the Trametinib drug treatment caused germline phenotypes consistent with ERK/mpk-1 loss. The new data in Fig. S1B shows that germlines treated with Tram are indeed defective. However, I am not confident that the brightfield microscopy permits us to say that these animals have the same phenotypes as ERK/mpk-1 loss. The experiment might be improved by different techniques: for example, use of fluorescent markers and DIC optics for live animals, or use of dyes or antibodies in fixed tissue. In the absence of different visualization methods, I would expect the authors to revise the claims.

Firstly, the claim in p. 7 line 131 is that the phenotypes resemble those “also observed when the MAPK is completely blocked.” Again, I agree that the germlines are defective, but the images shown do not enlighten us as to what way they are defective.

Secondly, the claim in p. 7 line 137 that “enlarged oocytes were observed.” I do not see a difference between the phenotype labeled “Enlarged oocyte” and “No oocyte.” Perhaps this figure would be improved if the authors would indicate where enlarged oocytes are located in their photograph.

2. Previously, I asked for data that would support a causative role for lin-45 in the protruding vulva (Pvl) phenotype. The new data in Fig. S1C shows that RNAi-mediated knockdown of lin-45 suppresses the Pvl phenotype of lin-45(V627E). I believe this information is an important foundation for of all the Pvl phenotype data. For this reason, it should be presented in the main Fig. 1 rather than the supplement.

3. For qualitative scoring data --the Pvl phenotypes and the germline oocyte phenotypes – I noted an absence of statistical information. I would expect all figures and supplemental figures to include the exact sample sizes per condition. I would also expect that differences between conditions be assessed using a test appropriate for count data (e.g. chi-squared or Fisher’s exact test).

Reviewer #2: The authors have addressed my concerns and revised the manuscript.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics  data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: No:  Numerical data that underlies graphs or summary statistics was not provided in spreadsheet form as supporting information. There were three supplemental tables, but these shared gene expression data, strains, or oligos--not underlying data in graphs, etc.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

Figure resubmission:

After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.

Reproducibility:

To enhance the reproducibility of your results, we recommend that authors deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 2

Kent W Hunter, Bruce E Clurman

26 Oct 2026

Dear Dr Ke,

We are pleased to inform you that your manuscript entitled "GPCR-Gαq Signaling Drives Adaptive Resistance to MEK Inhibition in BRAF-Mutant Melanoma" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Bruce E. Clurman

Academic Editor

PLOS Genetics

Kent Hunter

Section Editor

PLOS Genetics

Aimée Dudley

Editor-in-Chief

PLOS Genetics

Anne Goriely

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

BlueSky: @plos.bsky.social

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly:

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-26-00705R2

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Kent W Hunter, Bruce E Clurman

PGENETICS-D-26-00705R2

GPCR-Gαq Signaling Drives Adaptive Resistance to MEK Inhibition in BRAF-Mutant Melanoma

Dear Dr Ke,

We are pleased to inform you that your manuscript entitled "GPCR-Gαq Signaling Drives Adaptive Resistance to MEK Inhibition in BRAF-Mutant Melanoma" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Anitha Samidurai

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Conservation of the BRAF/LIN-45 activation-loop valine and characterization of lin-45(V627E) animals.

    (A) Multiple sequence alignment of C. elegans LIN-45 and its homologs in human (Homo sapiens, Hs), mouse (Mus musculus, Mm), and zebrafish (Danio rerio, Dr). The arrow indicates the conserved valine residue in the activation loop, whose substitution by glutamate (V627E) mimics phosphorylation and confers constitutive kinase activation. (B) Representative bright-field images of oocyte morphology in day 1 adult WT and lin-45(V627E) animals treated with DMSO or trametinib (Tram) at the indicated concentrations. Red arrows indicate enlarged oocyte-like compartments, and black arrowheads indicate their visible boundaries. Percentages indicate the proportion of animals displaying the indicated oocyte phenotype. Scale bar, 50 μm. (C) Quantification of the oocyte phenotypes shown in (B). The exact numbers of animals examined are shown in parentheses below the corresponding genotype labels. Phenotype distributions were compared between genotypes under each treatment condition using two-sided exact tests: Fisher’s exact test was used for 2 × 2 contingency tables, and the Fisher–Freeman–Halton exact test was used for the 2 × 3 contingency table at 1 μM. P values were adjusted using the Holm method. ****P < 0.0001; ns, not significant. (D) Representative bright-field images of vulval morphology in day 1 adult WT and lin-45(V627E) animals treated with Tram at the indicated concentrations. Dashed boxes indicate the vulval region. The corresponding quantification and statistical analysis are shown in Fig 1D. Scale bar, 10 μm.

    (TIF)

    pgen.1012373.s001.tif (8.7MB, tif)
    S2 Fig. Upregulation of egl-30/Gαq and contribution of PLC-PKC signaling to high-dose trametinib resistance in lin-45(V627E) mutants.

    (A) Principal component analysis (PCA) of RNA-seq profiles from lin-45(V627E) F1 animals treated with 100 μM or 10 μM trametinib (n = 3 independent biological replicates per condition). (B) Integrative Genomics Viewer (IGV) tracks showing normalized RNA-seq read coverage at the egl-30 locus in lin-45(V627E) F1 animals treated with 100 μM or 10 μM trametinib. (C) Representative bright-field images of wild-type (WT) and lin-45(V627E) animals, along with their progeny, following treatment with DMSO or trametinib (Tram) at the indicated concentrations for 10 days. Five adult animals were transferred per plate. Scale bar, 1 mm. (D) Schematic representation of Gαq–PLC–PKC signaling and the canonical RAS–RAF–MEK–ERK cascade as distinct but potentially interacting pathways regulating fertility. Solid arrows indicate established signaling relationships, whereas dashed arrows indicate possible pathway crosstalk or MAPK-independent contributions to fertility. The molecular targets of U73122, sotrastaurin (Sotra), and trametinib (Tram) are indicated. (E) Representative bright-field images of lin-45(V627E) animals along with their progeny, following treatment with DMSO, trametinib (100 μM), U73122 (50 μM), sotrastaurin (50 μM), or the indicated drug combinations for 10 days. Scale bar, 1 mm.

    (TIF)

    pgen.1012373.s002.tif (10.3MB, tif)
    S3 Fig. Inhibition of Gαq-PLC-PKC signaling reduces clonogenic growth of parental A375 cells.

    (A) Colony formation assay of A375 cells transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib at the indicated concentrations. Representative images of crystal violet-stained colonies (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (B) Colony formation assay of A375 cells treated with vehicle, trametinib (1 nM), U73122 (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates. (C) Colony formation assay of A375 cells treated with vehicle, trametinib (1 nM), sotrastaurin (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates.

    (TIF)

    pgen.1012373.s003.tif (3.1MB, tif)
    S4 Fig. Body weight monitoring of A375 xenograft-bearing mice during treatment.

    (A) Body weights of parental A375 xenograft-bearing mice treated with vehicle, U73122 (50 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 17 mice per group). (B) Body weights of parental A375 xenograft-bearing mice treated with vehicle, sotrastaurin (Sotra; 80 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 12 mice per group). Data represent mean ± SEM. Treatments were initiated when mean tumor volume reached ~250 mm3.

    (TIF)

    S5 Fig. Inhibition of Gαq-PLC-PKC signaling reduces clonogenic growth of trametinib-resistant A375 cells.

    (A) Colony formation assay of parental A375 and trametinib-resistant A375 (A375-TR) cells treated with vehicle or trametinib at the indicated concentrations. Representative images of crystal violet-stained colonies (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (B) Colony formation assay of A375-TR cells transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib at the indicated concentrations. Representative images (left) and quantification of colony area (right) are shown. n = 3 independent biological replicates. (C) Colony formation assay of A375-TR cells treated with vehicle, trametinib (1 nM), U73122 (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates. (D) Colony formation assay of A375-TR cells treated with vehicle, trametinib (1 nM), sotrastaurin (10 μM or 20 μM), or the indicated combinations. Representative images (top) and quantification of colony area (bottom) are shown. *P < 0.05, **P < 0.01, ****P < 0.0001; ns, not significant; one-way ANOVA with Tukey’s multiple comparisons test. n = 3 independent biological replicates.

    (TIF)

    pgen.1012373.s005.tif (4.2MB, tif)
    S6 Fig. Body weight monitoring of A375-TR xenograft-bearing mice during treatment.

    (A) Body weights of trametinib-resistant A375-TR xenograft-bearing mice treated with vehicle, U73122 (50 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 10 mice per group). (B) Body weights of A375-TR xenograft-bearing mice treated with vehicle, sotrastaurin (80 mg/kg), trametinib (0.2 mg/kg), or their combination (n = 10 mice per group). (C) Body weights of mice bearing A375-TR xenografts transduced with control vector (Ctrl) or shGαq/11 and treated with vehicle or trametinib (0.2 mg/kg) (n = 18 mice per group). Data represent mean ± SEM.

    (TIF)

    pgen.1012373.s006.tif (1.2MB, tif)
    S7 Fig. Dataset-specific expression changes of F2RL1 (PAR2), GNAQ, and GNA11 in melanoma samples before and after MAPK pathway inhibitor treatment.

    (A-C) Paired human melanoma samples from individual datasets (RNA-seq: 50535 and 77940; microarray: 50509 and 61992) were analyzed for F2RL1 (PAR2), GNAQ, and GNA11 mRNA levels pre-/post-treatment with BRAFi, MEKi, or combined BRAFi/MEKi. Numbers in each column indicate the number of sample pairs.

    (TIF)

    pgen.1012373.s007.tif (1.5MB, tif)
    S1 Table. RNA-seq analysis of Gαq-associated genes in lin-45(V627E) animals (100 vs. 10 μM trametinib).

    Differentially expressed Gαq-associated genes identified by RNA-seq in lin-45(V627E) animals treated with 100 or 10 μM trametinib.

    (XLSX)

    pgen.1012373.s008.xlsx (10.6KB, xlsx)
    S2 Table. Caenorhabditis elegans strains used in this study.

    Genotypes and descriptions of all C. elegans strains used in this work.

    (XLSX)

    pgen.1012373.s009.xlsx (10KB, xlsx)
    S3 Table. Plasmids and primers used in this study.

    Plasmids and shRNA oligonucleotide sequences used for gene knockdown in cultured cells.

    (XLSX)

    pgen.1012373.s010.xlsx (10.2KB, xlsx)
    S1. Rawgel.

    Uncropped gel images for western blots presented in this study.

    (PDF)

    pgen.1012373.s011.pdf (14.4MB, pdf)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pgen.1012373.s013.docx (66.3KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_auresp_2.docx

    pgen.1012373.s014.docx (17.7KB, docx)

    Data Availability Statement

    Data and materials availability: All data are available in the main text or supplementary materials. All sequencing data from this study have been submitted to the NCBI Sequence Read Archive (SRA; www.ncbi.nlm.nih.gov/sra) with BioProject accession numbers PRJNA1404971 and PRJNA1405274.


    Articles from PLOS Genetics are provided here courtesy of PLOS

    RESOURCES